首页>
外国专利>
SPARC-DERIVED TUMOR REJECTION ANTIGENIC PEPTIDES AND AGENTS INDUCING IMMUNITY AGAINST CANCERS COMPRISING THE SAME
SPARC-DERIVED TUMOR REJECTION ANTIGENIC PEPTIDES AND AGENTS INDUCING IMMUNITY AGAINST CANCERS COMPRISING THE SAME
展开▼
机译:SPARC衍生的肿瘤排斥抗原肽和引发免疫力的抗癌药物
展开▼
页面导航
摘要
著录项
相似文献
摘要
It is an objective of the present invention to identify SPARC protein-derived peptides that are able to induce human killer T cells and helper T cells having cytotoxic activity to tumors, and to provide a means for carrying out a tumor immunotherapy of patients with various types of cancers overexpressing SPARC. The present invention provides a peptide of any of the following: (A) a peptide which consists of the amino acid sequence as shown in any one of SEQ ID NOS: 1 to 3; or (B) a peptide which consists of an amino acid sequence comprising a substitution or addition of one or several amino acids with respect to the peptide consisting of the amino acid sequence as shown in any one of SEQ ID NOS: 1 to 3, and which has capacity to induce cytotoxic (killer) T cells.
展开▼
机译:本发明的目的是鉴定能够诱导对肿瘤具有细胞毒活性的人杀伤性T细胞和辅助性T细胞的SPARC蛋白来源的肽,并提供对各种类型的患者进行肿瘤免疫疗法的手段。过度表达SPARC的癌症。本发明提供以下任何一种的肽:(A)由SEQ ID NO:1至3中任一项所示的氨基酸序列组成的肽;要么(B)由氨基酸序列组成的肽,该氨基酸序列相对于由SEQ ID NOS:1-3中任一项所示的氨基酸序列组成的肽,包含一个或多个氨基酸的取代或添加,并且具有诱导细胞毒性(杀伤性)T细胞的能力。
展开▼